Generic molecule: ziv-aflibercept
Approval date: Aug. 3
The scoop: This treatment for colorectal cancer may be remembered less for its efficacy than for the precedent Sanofi ($SNY) set by halving the price on the treatment, three months after it was approved. The company put it on fire sale after three doctors from Memorial Sloan-Kettering Cancer Center announced in The New York Times that their hospital wouldn't be using Zaltrap because it wasn't any better than existing treatments, but its $9,600 a month price tag made it more expensive, something they said just won't play in the new fiscal realities of healthcare. Sanofi responded by acknowledging "market resistance" and said it would discount the drug. The question is what effect it will have on the pricing of other drugs and whether with the discount Sanofi might actually pick up market share from the established treatment Avastin from Roche.